Lommatzsch P K
Br J Ophthalmol. 1986 Nov;70(11):844-51. doi: 10.1136/bjo.70.11.844.
From 1964 to 1984 309 patients with choroidal melanoma were treated with 106Ru/106Rh beta ray applicators (1000 Gy at the apex of the tumour within 7-14 days). In cases 216 (69.9%) this treatment was successful for a mean follow-up period of 6.7 years after irradiation. In 53 cases (17.2%) the eye had to be enucleated, and 40 patients (12.9%) died from metastases within this period. Of the 216 successfully treated patients 114 (52.8%) developed flat scars and 49 (22.7%) retained a visual acuity of 1.5-0.5. Radiogenic late complications with damage to the retinal capillary system were the main causes of visual deterioration, especially in eyes with tumours close to the posterior pole. The survival rate is substantially higher than that for patients whose eyes were primarily enucleated. beta Ray applicators with 106Ru/106Rh can be recommended as an effective tool and a simple and cheap procedure to cure patients with small and medium sized choroidal melanomas. They save the eye without endangering our patients' lives.
1964年至1984年期间，309例脉络膜黑色素瘤患者接受了106Ru/106Rhβ射线敷贴器治疗（肿瘤顶端7至14天内剂量达1000戈瑞）。其中216例（69.9%）治疗成功，放疗后平均随访6.7年。53例（17.2%）患者不得不接受眼球摘除，40例（12.9%）患者在此期间死于转移。在216例治疗成功的患者中，114例（52.8%）出现扁平瘢痕，49例（22.7%）视力保留在1.5至0.5。放射性晚期并发症导致视网膜毛细血管系统受损是视力恶化的主要原因，尤其是肿瘤靠近后极的眼睛。其生存率显著高于主要接受眼球摘除的患者。106Ru/106Rhβ射线敷贴器可作为治疗中小型脉络膜黑色素瘤患者的有效工具，是一种简单且廉价的方法。它能保住眼球，同时不危及患者生命。
